Y
Yan Feng
Publications - 17
Citations - 417
Yan Feng is an academic researcher. The author has contributed to research in topics: Aryl & Glycosidic bond. The author has an hindex of 12, co-authored 17 publications receiving 402 citations.
Papers
More filters
Patent
Benzylbenzene derivatives and methods of use
Yuanwei Chen,Cheng Huawei,Shengbin Li,Wu Yuelin,Yan Feng,Binhua Lv,Baihua Xu,Brian Seed,Michael J. Hadd,Yanli Song,Jiyan Du,Congna Wang,Jacques Y. Roberge +12 more
TL;DR: In this paper, compounds having an inhibitory effect on sodium-dependent glucose cotransporter SGLT are provided. And the authors also provide pharmaceutical compositions, methods of preparing the compounds, synthetic intermediates, and methods of using the compounds independently or in combination with other therapeutic agents, for treating diseases and conditions which are affected by sGLT inhibition.
Patent
Glucose transport inhibitors and methods of use
TL;DR: In this article, compounds having an inhibitory effect on sodium-dependent glucose cotransporter SGLT are provided. And the authors also provide pharmaceutical compositions, methods of preparing the compounds, synthetic intermediates, and methods of using the compounds independently or in combination with other therapeutic agents, for treating diseases and conditions which are affected by sGLT inhibition.
Journal ArticleDOI
Design, synthesis, and biological evaluation of deuterated C-aryl glycoside as a potent and long-acting renal sodium-dependent glucose cotransporter 2 inhibitor for the treatment of type 2 diabetes.
Ge Xu,Binhua Lv,Jacques Y. Roberge,Baihua Xu,Jiyan Du,Jiajia Dong,Yuanwei Chen,Kun Peng,Lili Zhang,Xinxing Tang,Yan Feng,Min Xu,Wei Fu,Wenbin Zhang,Liangcheng Zhu,Zhongping Deng,Zelin Sheng,Ajith Welihinda,Xun Sun +18 more
TL;DR: S GLT2 inhibitors deuterated at sites susceptible to oxidative metabolism were found to have a slightly longer tmax and half-life, dose-dependent increase in urinary glucose excretion in rats, and slightly superior effects on UGE in dogs while retaining similar in vitro inhibitory activities against hSGLT2.
Journal ArticleDOI
Exploration of O-spiroketal C-arylglucosides as novel and selective renal sodium-dependent glucose co-transporter 2 (SGLT2) inhibitors.
Binhua Lv,Baihua Xu,Yan Feng,Kun Peng,Ge Xu,Jiyan Du,Lili Zhang,Wenbin Zhang,Ting Zhang,Liangcheng Zhu,Haifeng Ding,Zelin Sheng,Ajith Welihinda,Brian Seed,Yuanwei Chen +14 more
TL;DR: The core spiro[isobenzofuran-1,2'-pyran] structure proved to be an effective scaffold for diversification and a number of compounds with single digit nanomolar potency and high selectivity have been synthesized.
Patent
Benzylic glycoside derivatives and methods of use
Yuanwei Chen,Yan Feng,Baihua Xu,Binhua Lv,Brian Seed,Michael J. Hadd,Cheng Huawei,Zelin Sheng,Min Xu,Congna Wang,Jiyan Du,Lili Zhang,Ge Xu,Wu Yuelin +13 more
TL;DR: In this paper, compounds having an inhibitory effect on sodium-dependent glucose cotransporter SGLT are provided. And the authors also provide pharmaceutical compositions, methods of preparing the compounds, synthetic intermediates, and methods of using the compounds independently or in combination with other therapeutic agents, for treating diseases and conditions which are affected by sGLT inhibition.